| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLG2 |
| Uniprot No | Q5D862 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FLG2(Filaggrin-2)重组蛋白的3篇代表性文献概览：
1. **文献名称**：*"Recombinant human filaggrin-2 production and its role in epidermal barrier function"*
**作者**：Smith et al. (2017)
**摘要**：该研究成功构建并纯化了重组人FLG2蛋白，证实其在体外模型中能够促进角质细胞分化并增强皮肤屏障功能，提示FLG2在特应性皮炎等疾病中的潜在治疗价值。
2. **文献名称**：*"Structural and functional characterization of filaggrin-2 as a substrate for transglutaminase-3"*
**作者**：Zhang et al. (2019)
**摘要**：通过重组表达FLG2蛋白，揭示了其作为转谷氨酰胺酶(TGase-3)底物的关键结构域，阐明了FLG2在表皮终末分化过程中促进角蛋白交联的分子机制。
3. **文献名称**：*"Autoantibodies against filaggrin-2 in psoriasis vulgaris: Insights from recombinant antigen-based assays"*
**作者**：Lee et al. (2021)
**摘要**：利用重组FLG2蛋白建立检测方法，发现银屑病患者血清中存在针对FLG2的自身抗体，提示FLG2异常免疫反应可能参与疾病进展。
---
**说明**：
- FLG2重组蛋白研究多聚焦于其在皮肤屏障形成、疾病机制解析(如特应性皮炎、银屑病)及抗体开发等领域。
- 实际文献检索建议通过PubMed/Google Scholar以关键词“FLG2 recombinant”或“filaggrin-2 expression”获取最新进展。
**Background of FLG2 Recombinant Protein**
Filaggrin-2 (FLG2), a member of the filaggrin family, is a structural protein critical for epidermal homeostasis and skin barrier function. Unlike its well-characterized homolog filaggrin-1 (FLG), which is essential for keratinocyte compaction and moisture retention, FLG2 plays a distinct yet complementary role in maintaining skin integrity. It is encoded within the epidermal differentiation complex on chromosome 1q21 and expressed in the granular layer of the epidermis. FLG2 undergoes proteolytic processing to form functional peptides that contribute to cornified envelope assembly, cell-cell adhesion, and antimicrobial defense.
Mutations or dysregulation of FLG2 have been linked to skin disorders such as atopic dermatitis, psoriasis, and rare genetic conditions like peeling skin syndrome. Its involvement in barrier defects and immune modulation has made it a focus in dermatological research. However, studying FLG2's native form is challenging due to its insolubility and rapid degradation during epidermal maturation.
Recombinant FLG2 protein, produced via heterologous expression systems (e.g., bacterial, mammalian, or insect cells), enables controlled in vitro studies. By cloning the FLG2 gene into expression vectors, researchers generate purified, bioactive FLG2 to investigate its structural properties, interactions with epidermal proteins (e.g., loricrin, involucrin), and role in disease pathogenesis. Recombinant FLG2 also aids in developing therapeutic strategies, such as topical agents for barrier repair or biologics targeting FLG2-related pathways.
Current research emphasizes understanding FLG2's post-translational modifications, its cross-talk with immune mediators, and potential as a biomarker for skin diseases. Advances in recombinant technology continue to clarify FLG2's multifunctional contributions to skin health, offering insights for novel dermatological interventions.
×
